Table 1 Patients’ demographics and clinicopathological characteristics (n = 290)
Age at diagnosis | Patients (n, %) |
|---|---|
<40 | 7 (2.4) |
40-50 | 53 (18.3) |
51-60 | 71 (24.5) |
>60 | 159 (54.8) |
Diagnosis | Â |
Invasive carcinoma (NST) | 208 (71.7) |
ILC | 31 (10.7) |
DCIS | 33 (11.4) |
Other | 18 (6.2) |
DCIS status* | Â |
Invasive carcinomas without DCIS | 93 (36.3) |
Invasive carcinomas with DCIS | 163 (63.7) |
DCIS grade | Â |
DCIS grade 1-2 | 77 (39.3) |
DCIS grade 3 | 119 (60.7) |
Hormone receptor status | Â |
ER neg / pos / na | 44 (15.2) / 210 (72.4) / 36 (12.4) |
PR neg / pos / na | 59 (20.3) / 122 (42.1) / 109 (37.6) |
HER2 neg / pos / na | 215 (74.1) / 40 (13.8) / 35 (12.1) |
Tumor size | Â |
≤20 mm | 159 (62.1) |
21- 50Â mm | 87 (34.0) |
>50Â mm | 10 (3.9) |
Histological grade* | Â |
1 | 85 (33.3) |
2 | 121 (47.5) |
3 | 49 (19.2) |
Lymph node involvement | Â |
Negative | 204 (70.3) |
Positive | 86 (29.7) |
Involved lymph nodes | Â |
1-3 | 62 (72.1) |
>3 | 24 (27.9) |
Immune cell infiltration* | Â |
No infiltration | 39 (13.5) |
Mild infiltration | 144 (49.8) |
Moderate infiltration | 90 (31.1) |
Extensive infiltration | 16 (5.6) |
Aggregate formation* | Â |
Negative | 143 (49.5) |
Positive | 146 (50.5) |
TLS formation* | Â |
Negative | 175 (61.4) |
Positive | 110 (38.6) |